The University of Southampton
University of Southampton Institutional Repository

Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
Mutations in the Bcr-Abl kinase domain (KD) may cause, or contribute to, resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) patients. Recommendations aimed to rationalize the use of BCR-ABL mutation testing in CML have been compiled by a panel of experts appointed by the European LeukemiaNet (ELN) and European Treatment and Outcome Study (EUTOS) and are here reported. Based on a critical review of the literature and, whenever necessary, on panelists' experience, key issues were identified and discussed concerning: i) when to perform mutation analysis; ii) how to perform it; iii) how to translate results into clinical practice. In chronic phase patients receiving imatinib first-line, mutation analysis is recommended only in case of failure or suboptimal response according to the ELN criteria. In imatinib-resistant patients receiving an alternative TKI, mutation analysis is recommended in case of hematologic or cytogenetic failure as provisionally defined by the ELN. The recommended methodology is direct sequencing, although it may be preceded by screening with other techniques like denaturing-high performance liquid chromatography. In all the cases outlined above, a positive result is an indication for therapeutic change. Some specific mutations weigh on TKI selection.

0006-4971
1208-1215
Soverini, Simona
a43c135a-5658-4429-93dc-1855227574a1
Hochhaus, Andreas
b37b9b7d-85ff-455e-994d-fcc2adf94088
Nicolini, Franck E.
684f5de2-b569-4429-ac90-bdf38a8c48c1
Gruber, Franz
e398a5b9-7b1a-467a-aae2-4c973c37e547
Lange, Thoralf
25789639-fb54-4dbe-ac83-1c3658261a9c
Saglio, Giuseppe
46ec4e74-92c7-4459-ac47-0b10cbcd887e
Pane, Fabrizio
82663d99-c04b-4564-85b7-9a9e1574d541
Muller, Martin C.
34ec2215-e464-4320-a867-cc64a6b3dc38
Ernst, Thomas
96c7805b-c900-4545-9f93-1a83d789cb56
Rosti, Gianantonio
c5844359-77d9-4325-a7e8-96992dc1f294
Porkka, Kimmo
0799819b-593e-476f-8875-ae23aca51bcd
Baccarani, Michele
91de1e74-01f2-46cc-9d93-846e372ce8ef
Cross, Nicholas C.P.
f87650da-b908-4a34-b31b-d62c5f186fe4
Martinelli, Giovanni
4a5508fd-7178-45ca-90dd-c7692af77776
Soverini, Simona
a43c135a-5658-4429-93dc-1855227574a1
Hochhaus, Andreas
b37b9b7d-85ff-455e-994d-fcc2adf94088
Nicolini, Franck E.
684f5de2-b569-4429-ac90-bdf38a8c48c1
Gruber, Franz
e398a5b9-7b1a-467a-aae2-4c973c37e547
Lange, Thoralf
25789639-fb54-4dbe-ac83-1c3658261a9c
Saglio, Giuseppe
46ec4e74-92c7-4459-ac47-0b10cbcd887e
Pane, Fabrizio
82663d99-c04b-4564-85b7-9a9e1574d541
Muller, Martin C.
34ec2215-e464-4320-a867-cc64a6b3dc38
Ernst, Thomas
96c7805b-c900-4545-9f93-1a83d789cb56
Rosti, Gianantonio
c5844359-77d9-4325-a7e8-96992dc1f294
Porkka, Kimmo
0799819b-593e-476f-8875-ae23aca51bcd
Baccarani, Michele
91de1e74-01f2-46cc-9d93-846e372ce8ef
Cross, Nicholas C.P.
f87650da-b908-4a34-b31b-d62c5f186fe4
Martinelli, Giovanni
4a5508fd-7178-45ca-90dd-c7692af77776

Soverini, Simona, Hochhaus, Andreas, Nicolini, Franck E., Gruber, Franz, Lange, Thoralf, Saglio, Giuseppe, Pane, Fabrizio, Muller, Martin C., Ernst, Thomas, Rosti, Gianantonio, Porkka, Kimmo, Baccarani, Michele, Cross, Nicholas C.P. and Martinelli, Giovanni (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood, 118 (5), 1208-1215. (doi:10.1182/blood-2010-12-326405). (PMID:21562040)

Record type: Article

Abstract

Mutations in the Bcr-Abl kinase domain (KD) may cause, or contribute to, resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) patients. Recommendations aimed to rationalize the use of BCR-ABL mutation testing in CML have been compiled by a panel of experts appointed by the European LeukemiaNet (ELN) and European Treatment and Outcome Study (EUTOS) and are here reported. Based on a critical review of the literature and, whenever necessary, on panelists' experience, key issues were identified and discussed concerning: i) when to perform mutation analysis; ii) how to perform it; iii) how to translate results into clinical practice. In chronic phase patients receiving imatinib first-line, mutation analysis is recommended only in case of failure or suboptimal response according to the ELN criteria. In imatinib-resistant patients receiving an alternative TKI, mutation analysis is recommended in case of hematologic or cytogenetic failure as provisionally defined by the ELN. The recommended methodology is direct sequencing, although it may be preceded by screening with other techniques like denaturing-high performance liquid chromatography. In all the cases outlined above, a positive result is an indication for therapeutic change. Some specific mutations weigh on TKI selection.

This record has no associated files available for download.

More information

Accepted/In Press date: 11 May 2011
Published date: 4 August 2011

Identifiers

Local EPrints ID: 194309
URI: http://eprints.soton.ac.uk/id/eprint/194309
ISSN: 0006-4971
PURE UUID: c9da2fc1-f753-4f32-80fe-ce524585fd8b
ORCID for Nicholas C.P. Cross: ORCID iD orcid.org/0000-0001-5481-2555

Catalogue record

Date deposited: 27 Jul 2011 08:16
Last modified: 15 Mar 2024 03:11

Export record

Altmetrics

Contributors

Author: Simona Soverini
Author: Andreas Hochhaus
Author: Franck E. Nicolini
Author: Franz Gruber
Author: Thoralf Lange
Author: Giuseppe Saglio
Author: Fabrizio Pane
Author: Martin C. Muller
Author: Thomas Ernst
Author: Gianantonio Rosti
Author: Kimmo Porkka
Author: Michele Baccarani
Author: Giovanni Martinelli

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×